Hossein Ayatollahi1, Arezoo Shajiei2, Mohammad Hadi Sadeghian2, Maryam Sheikhi3, Ehsan Yazdandoust2, Masumeh Ghazanfarpour4, Seyyede Fatemeh Shams2, Sepideh Shakeri2. 1. Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Hematology and Blood Bank, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sheikhim75@gmail.com. 4. Department of Midwifery, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
OBJECTIVE/ BACKGROUND: Acute myeloid leukemia (AML) is defined as leukemic blast reproduction in bone marrow. Chromosomal abnormalities form different subgroups with joint clinical specifications and results. t(8;21)(q22;q22) and inv(16)(p13;q22) form core binding factor-AML (CBF-AML). c-kit mutation activation occurs in 12.8-46.1% of adults with CBF leukemia. These mutations occur in 20-25% of t(8;21) and 30% of inv(16) cases. METHODS: In this systematic review, we searched different databases, including PubMed, Scopus, and Embase. Selected articles were measured based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, articles relevant to the subject of this review were retrieved in full text. Twenty-two articles matched the inclusion criteria and were selected for this review. RESULTS: In this study, c-kit mutations were associated with poor prognosis in AML patients with t(8;21) and inv(16). In addition, these mutations had better prognostic effects on AML patients with inv(16) compared with those with t(8;21). CONCLUSION: According to the results of this study, c-kit mutations have intense, harmful effects on the relapse and white blood cell increase in CBF-AML adults. However, these mutations have no significant prognostic effects on patients.
OBJECTIVE/ BACKGROUND:Acute myeloid leukemia (AML) is defined as leukemic blast reproduction in bone marrow. Chromosomal abnormalities form different subgroups with joint clinical specifications and results. t(8;21)(q22;q22) and inv(16)(p13;q22) form core binding factor-AML (CBF-AML). c-kit mutation activation occurs in 12.8-46.1% of adults with CBF leukemia. These mutations occur in 20-25% of t(8;21) and 30% of inv(16) cases. METHODS: In this systematic review, we searched different databases, including PubMed, Scopus, and Embase. Selected articles were measured based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, articles relevant to the subject of this review were retrieved in full text. Twenty-two articles matched the inclusion criteria and were selected for this review. RESULTS: In this study, c-kit mutations were associated with poor prognosis in AMLpatients with t(8;21) and inv(16). In addition, these mutations had better prognostic effects on AMLpatients with inv(16) compared with those with t(8;21). CONCLUSION: According to the results of this study, c-kit mutations have intense, harmful effects on the relapse and white blood cell increase in CBF-AML adults. However, these mutations have no significant prognostic effects on patients.
Authors: Stephen A Strickland; Aaron C Shaver; Michael Byrne; Robert D Daber; P Brent Ferrell; David R Head; Sanjay R Mohan; Claudio A Mosse; Tamara K Moyo; Thomas P Stricker; Cindy Vnencak-Jones; Michael R Savona; Adam C Seegmiller Journal: Leuk Res Date: 2018-01-02 Impact factor: 3.156
Authors: Fan Zhou; Fen Zhou; Mengyi Du; Lin Liu; Tao Guo; Linghui Xia; Runming Jin; Yu Hu; Heng Mei Journal: Int J Hematol Date: 2019-08-22 Impact factor: 2.490
Authors: Soheil Meshinchi; Jessica A Pollard; Katherine Tarlock; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Rhonda Ries; Michael R Loken; Laura Pardo; Tiffany Hylkema; Jason Joaquin; Leela Sarukkai; Susana C Raimondi; Betsy Hirsch; Lillian Sung; Richard Aplenc; Irwin Bernstein; Alan S Gamis Journal: Clin Cancer Res Date: 2019-06-10 Impact factor: 12.531
Authors: Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge Journal: Signal Transduct Target Ther Date: 2020-12-18